Company Filing History:
Years Active: 2000-2006
Title: Martine Latta: Innovator in Recombinant Adenoviruses
Introduction
Martine Latta is a prominent inventor based in Charenton le Pont, France. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant adenoviruses. With a total of five patents to her name, her work has implications for gene therapy and pharmaceutical compositions.
Latest Patents
Latta's latest patents include innovative methods involving recombinant adenoviruses. One notable patent describes a recombinant adenovirus where the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is controlled by an inducible promoter. This invention also covers the use of such recombinant adenoviruses for preparing AAVs, along with a complementary cell line and preparation methods. Another patent focuses on targeted adenovirus vectors for the delivery of heterologous genes. This modification allows for effective targeting of adenovirus vectors by identifying accessible sites on the adenovirus fiber protein and hexon protein. These advancements are particularly useful for gene therapy applications in treating cancers and cardiovascular conditions.
Career Highlights
Throughout her career, Martine Latta has worked with notable companies in the pharmaceutical industry, including Aventis Pharma S.A. and Rhône-Poulenc Rorer S.A. Her experience in these organizations has contributed to her expertise in the development of innovative biotechnological solutions.
Collaborations
Latta has collaborated with esteemed colleagues in her field, including Emmanuelle Vigne and Michel Perricaudet. These partnerships have fostered a collaborative environment that enhances the research and development of her inventions.
Conclusion
Martine Latta's contributions to the field of recombinant adenoviruses demonstrate her innovative spirit and commitment to advancing biotechnology. Her patents and collaborations reflect her significant impact on gene therapy and pharmaceutical development.